Payment overview · 2025
General Payments
$549.08
15 reported records · 9 companies
Healthcare provider profile · identity verified
Ignacio Acevedo, MD
Allopathic & Osteopathic Physicians|General Practice · MANATI, PR · NPI 1407942212
Verified facts
What the public records show
CMS Open Payments records show Ignacio Acevedo, MD received $549.08 in general payments during 2025 across 15 reported records.
PBG PUERTO RICO LLC accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 738 records involving 435 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PBG PUERTO RICO LLC | Unresolved — no canonical attribution shown | $114.73 | 20.9% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$92.96 | 16.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $78.09 | 14.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $75.00 | 13.7% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $62.98 | 11.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $57.86 | 10.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.00 | 4.5% | 1 | 2025 |
| Bayer Puerto Rico Inc. | Unresolved — no canonical attribution shown | $23.41 | 4.3% | 1 | 2025 |
| Eli Lilly Export S.A. Puerto Rico Branch | Unresolved — no canonical attribution shown | $19.05 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $549.08 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc., Bayer Puerto Rico Inc. | $101.50 | 2 | 2025 |
Source payment records
|
|||||
| SOLITAIRE X Normalized: solitaire x |
Device | Medtronic, Inc. | $92.96 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PBG PUERTO RICO LLC | $68.67 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $62.98 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.86 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PBG PUERTO RICO LLC | $47.27 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $19.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
187 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 738 supporting records · 435 recipient NPIs · example record 1228798592 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
59 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 822 | 98 |
| Famotidine | Famotidine | 587 | 113 |
| Atorvastatin Calcium | Atorvastatin Calcium | 420 | 125 |
| Levothyroxine Sodium | Levothyroxine Sodium | 282 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 280 | 84 |
| Lisinopril | Lisinopril | 270 | 80 |
| Metformin Hcl | Metformin Hcl | 264 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 244 | 39 |
| Alendronate Sodium | Alendronate Sodium | 238 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 219 | 65 |
| Synthroid | Levothyroxine Sodium | 187 | 25 |
| Montelukast Sodium | Montelukast Sodium | 170 | 29 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 169 | 30 |
| Losartan Potassium | Losartan Potassium | 166 | 54 |
| Nabumetone | Nabumetone | 153 | 46 |
| Hydralazine Hcl | Hydralazine Hcl | 152 | 37 |
| Omeprazole | Omeprazole | 147 | 42 |
| Finasteride | Finasteride | 133 | 22 |
| Sucralfate | Sucralfate | 130 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 19 |
| Simvastatin | Simvastatin | 106 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 36 |
| Warfarin Sodium | Warfarin Sodium | 93 | suppressed |
| Naproxen | Naproxen | 90 | 34 |
| Buspirone Hcl | Buspirone Hcl | 88 | 19 |
| Carvedilol | Carvedilol | 82 | 23 |
| Ezetimibe | Ezetimibe | 74 | 24 |
| Baclofen | Baclofen | 73 | 30 |
| Diclofenac Potassium | Diclofenac Potassium | 71 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 24 |
| Eliquis | Apixaban | 59 | 16 |
| Donepezil Hcl | Donepezil Hcl | 56 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 26 |
| Furosemide | Furosemide | 55 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 55 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 17 |
| Albuterol Sulfate | Albuterol Sulfate | 48 | 28 |
| Prednisone | Prednisone | 48 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 46 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 14 |
| Glimepiride | Glimepiride | 45 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 44 | 27 |
| Raloxifene Hcl | Raloxifene Hcl | 44 | suppressed |
| Clonazepam | Clonazepam | 42 | suppressed |
| Humalog | Insulin Lispro | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | suppressed |
| Glipizide | Glipizide | 35 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 30 |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Pentoxifylline | Pentoxifylline | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | 12 |
| Atenolol | Atenolol | 29 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Spironolactone | Spironolactone | 26 | 12 |
| Cilostazol | Cilostazol | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 22 |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 24 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 24 | 11 |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Azithromycin | Azithromycin | 23 | 21 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 18 |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Sulindac | Sulindac | 17 | suppressed |
| Metronidazole | Metronidazole | 16 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Sure Comfort | Syring-Needl,disp,insul,0.3 Ml | 14 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Glipizide Er | Glipizide | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $549.08 · 15 records | PBG PUERTO RICO LLC | CAPVAXIVE, ELIQUIS, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, SOLITAIRE X, VYALEV, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error